28 research outputs found
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
Adoptive immunotherapy using chimeric antigen receptor (CAR)-T cells has achieved
successful remissions in refractory B-cell leukemia and B-cell lymphomas. In order to
estimate both success and severe side effects of CAR-T cell therapies, longitudinal
monitoring of the patient’s immune system including CAR-T cells is desirable to
accompany clinical staging. To conduct research on the fate and immunological impact
of infused CAR-T cells, we established standardized 13-colour/15-parameter flow
cytometry assays that are suitable to characterize immune cell subpopulations in the
peripheral blood during CAR-T cell treatment. The respective staining technology is based
on pre-formulated dry antibody panels in a uniform format. Additionally, further antibodies
of choice can be added to address specific clinical or research questions. We designed
panels for the anti-CD19 CAR-T therapy and, as a proof of concept, we assessed a
healthy individual and three B-cell lymphoma patients treated with anti-CD19 CAR-T cells.
We analyzed the presence of anti-CD19 CAR-T cells as well as residual CD19+ B cells, the
activation status of the T-cell compartment, the expression of co-stimulatory signaling
molecules and cytotoxic agents such as perforin and granzyme B. In summary, this work
introduces standardized and modular flow cytometry assays for CAR-T cell clinical
research, which could also be adapted in the future as quality controls during the CART
cell manufacturing process
Restricting datasets to classifiable samples augments discovery of immune disease biomarkers
Immunological diseases are typically heterogeneous in clinical presentation, severity and response to therapy. Biomarkers of immune diseases often reflect this variability, especially compared to their regulated behaviour in health. This leads to a common difficulty that frustrates biomarker discovery and interpretation – namely, unequal dispersion of immune disease biomarker expression between patient classes necessarily limits a biomarker’s informative range. To solve this problem, we introduce dataset restriction, a procedure that splits datasets into classifiable and unclassifiable samples. Applied to synthetic flow cytometry data, restriction identifies biomarkers that are otherwise disregarded. In advanced melanoma, restriction finds biomarkers of immune-related adverse event risk after immunotherapy and enables us to build multivariate models that accurately predict immunotherapy-related hepatitis. Hence, dataset restriction augments discovery of immune disease biomarkers, increases predictive certainty for classifiable samples and improves multivariate models incorporating biomarkers with a limited informative range. This principle can be directly extended to any classification task
External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
Immune checkpoint inhibitors have revolutionized treatment of advanced melanoma, but commonly cause serious immune-mediated complications. The clinical ambition of reserving more aggressive therapies for patients least
likely to experience immune-related adverse events (irAE) has driven an extensive search for predictive biomarkers. Here, we externally validate the performance of 59 previously reported markers of irAE risk in a new cohort of 110 patients receiving Nivolumab (anti-PD1) and Ipilimumab (anti-CTLA-4) therapy. Alone or combined, the discriminatory value of these routine clinical parameters and flow cytometry biomarkers was poor. Unsupervised clustering of flow cytometry data returned four T cell subsets with higher discriminatory capacity for colitis than previously reported populations, but they cannot be
considered as reliable classifiers. Although mechanisms predisposing some patients to particular irAEs have been described, we are presently unable to capture adequate information from pre-therapy flow cytometry and clinical
data to reliably predict risk of irAE in most cases
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials (vol 395, pg 1627, 2020)
Advances in Cardiovascular Disease Lipid Research Can Provide Novel Insights Into Mycobacterial Pathogenesis
Cardiovascular disease (CVD) is the leading cause of death in industrialized nations and an emerging health problem in the developing world. Systemic inflammatory processes associated with alterations in lipid metabolism are a major contributing factor that mediates the development of CVDs, especially atherosclerosis. Therefore, the pathways promoting alterations in lipid metabolism and the interplay between varying cellular types, signaling agents, and effector molecules have been well-studied. Mycobacterial species are the causative agents of various infectious diseases in both humans and animals. Modulation of host lipid metabolism by mycobacteria plays a prominent role in its survival strategy within the host as well as in disease pathogenesis. However, there are still several knowledge gaps in the mechanistic understanding of how mycobacteria can alter host lipid metabolism. Considering the in-depth research available in the area of cardiovascular research, this review presents an overview of the parallel areas of research in host lipid-mediated immunological changes that might be extrapolated and explored to understand the underlying basis of mycobacterial pathogenesis
E-LDL and Ox-LDL differentially regulate ceramide and cholesterol raft microdomains in human Macrophages
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
Adoptive immunotherapy using chimeric antigen receptor (CAR)-T cells has achieved
successful remissions in refractory B-cell leukemia and B-cell lymphomas. In order to
estimate both success and severe side effects of CAR-T cell therapies, longitudinal
monitoring of the patient’s immune system including CAR-T cells is desirable to
accompany clinical staging. To conduct research on the fate and immunological impact
of infused CAR-T cells, we established standardized 13-colour/15-parameter flow
cytometry assays that are suitable to characterize immune cell subpopulations in the
peripheral blood during CAR-T cell treatment. The respective staining technology is based
on pre-formulated dry antibody panels in a uniform format. Additionally, further antibodies
of choice can be added to address specific clinical or research questions. We designed
panels for the anti-CD19 CAR-T therapy and, as a proof of concept, we assessed a
healthy individual and three B-cell lymphoma patients treated with anti-CD19 CAR-T cells.
We analyzed the presence of anti-CD19 CAR-T cells as well as residual CD19+ B cells, the
activation status of the T-cell compartment, the expression of co-stimulatory signaling
molecules and cytotoxic agents such as perforin and granzyme B. In summary, this work
introduces standardized and modular flow cytometry assays for CAR-T cell clinical
research, which could also be adapted in the future as quality controls during the CART
cell manufacturing process
Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications
Treatment of advanced melanoma with combined immune checkpoint inhibitor (ICI) therapy is complicated in up to 50% of cases by immune-related adverse events (irAE) that commonly include hepatitis, colitis and skin reactions. We previously reported that pre-therapy expansion of cytomegalovirus (CMV)-reactive CD4+ effector memory T cells (TEM) predicts ICI-related hepatitis in a subset of patients with Stage IV melanoma given αPD-1 and αCTLA-4. Here, we develop and validate a 10-color flow cytometry panel for reliably quantifying CD4+ TEM cells and other biomarkers of irAE risk in peripheral blood samples. Compared to previous methods, our new panel performs equally well in measuring CD4+ TEM cells (agreement = 98%) and is superior in resolving CD4+ CD197+ CD45RA- central memory T cells (TCM) from CD4+ CD197+ CD45RA+ naive T cells (Tnaive). It also enables us to precisely quantify CD14+ monocytes (CV = 6.6%). Our new “monocyte and T cell” (MoT) assay predicts immune-related hepatitis with a positive predictive value (PPV) of 83% and negative predictive value (NPV) of 80%. Our essential improvements open the possibility of sharing our predictive methods with other clinical centers. Furthermore, condensing measurements of monocyte and memory T cell subsets into a single assay simplifies our workflows and facilitates computational analyses
Advanced Flow Cytometry Assays for Immune Monitoring of CAR-T Cell Applications
Adoptive immunotherapy using chimeric antigen receptor (CAR)-T cells has achieved
successful remissions in refractory B-cell leukemia and B-cell lymphomas. In order to
estimate both success and severe side effects of CAR-T cell therapies, longitudinal
monitoring of the patient’s immune system including CAR-T cells is desirable to
accompany clinical staging. To conduct research on the fate and immunological impact
of infused CAR-T cells, we established standardized 13-colour/15-parameter flow
cytometry assays that are suitable to characterize immune cell subpopulations in the
peripheral blood during CAR-T cell treatment. The respective staining technology is based
on pre-formulated dry antibody panels in a uniform format. Additionally, further antibodies
of choice can be added to address specific clinical or research questions. We designed
panels for the anti-CD19 CAR-T therapy and, as a proof of concept, we assessed a
healthy individual and three B-cell lymphoma patients treated with anti-CD19 CAR-T cells.
We analyzed the presence of anti-CD19 CAR-T cells as well as residual CD19+ B cells, the
activation status of the T-cell compartment, the expression of co-stimulatory signaling
molecules and cytotoxic agents such as perforin and granzyme B. In summary, this work
introduces standardized and modular flow cytometry assays for CAR-T cell clinical
research, which could also be adapted in the future as quality controls during the CART
cell manufacturing process